Unknown

Dataset Information

PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy.


ABSTRACT:

Background

Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, in addition to its antiangiogenic properties, sorafenib may beneficially reduce the extent of the immunosuppressive network in HCC patients. To test this hypothesis, we examined whether alterations in the immunosuppressive burden of advanced-stage HCC patients correlated with clinical outcome.

Methods

In before and after sorafenib treatment, blood samples collected from 19 patients with advanced HCC, the frequency of PD-1+ T cells, Tregs, and myeloid derived suppressor cells (MDSC) were quantified by multiparameter FACS. Cytokine levels in plasma were determined by ELISA.

Results

Ov

SUBMITTER: Kalathil SG 

PROVIDER: S-EPMC4986927 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature